Comparative Pharmacology
Head-to-head clinical analysis: SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE versus SULTEN 10.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE versus SULTEN 10.
SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE vs SULTEN-10
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfacetamide sodium inhibits bacterial dihydropteroate synthase, blocking folate synthesis; prednisolone sodium phosphate suppresses inflammation by binding glucocorticoid receptors, inhibiting phospholipase A2 and pro-inflammatory cytokine production.
Selectively inhibits type 5 phosphodiesterase (PDE5), enhancing cyclic guanosine monophosphate (cGMP) accumulation, leading to smooth muscle relaxation and vasodilation in the corpus cavernosum.
1-2 drops into the conjunctival sac of the affected eye(s) every 2-4 hours during the day and at bedtime; frequency may be decreased as clinical signs improve.
1 to 2 tablets (10-20 mg) orally once daily, preferably in the morning.
None Documented
None Documented
Sulfacetamide: 6-8 hours (prolonged in renal impairment). Prednisolone: 2-4 hours (terminal half-life). Clinically, systemic effects may persist longer due to tissue distribution.
Terminal elimination half-life is 12-15 hours; clinically, this supports once-daily dosing with steady state achieved in 3-5 days.
Renal excretion of unchanged sulfacetamide (60-75%) and prednisolone metabolites (primarily conjugated); minimal biliary/fecal elimination (<10% for each).
Primarily renal excretion of unchanged drug (approx. 70-80%) with the remainder as inactive metabolites (10-15% fecal, 5-10% biliary).
Category A/B
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic